For this second talk in our high risk smoldering myeloma series, we have Prof. Jesus San Miguel from University of Navarra, Spain discuss his team's investigations into high-risk smoldering myeloma and probable cure. For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention. Our myeloma panel is talking to Prof. Jesus San Miguel about his research, clinical trials in the pipeline and future of myeloma treatment.
Prof. Miguel graduated in Medicine from the University of Navarra, was awarded his doctorate and recognised as an expert in Haematology by the University of Salamanca. He is currently the Head of Clinical and Translational Medicine at the Clínica Universidad de Navarra, which includes roles such as Medical Director of the Clínica Universidad de Navarra, Scientific Director of CIMA and Vice-Dean of Research at the University of Navarra. Previously, he was Head of the Haematology Unit at the University Hospital of Salamanca, Researcher and Deputy Director of the Cancer Research Centre, Scientific Director of the Biomedical Research Institute of Salamanca (IBSAL), Director of studies at the University Hospital of Salamanca, Deputy Director of the Medicine Department at the University of Salamanca and a member of the Research Commission at the University of Salamanca.
Sorry we couldn't complete your registration. Please try again.
You must accept the Terms and conditions to register